Possibia

6615479

Last Update Posted: 2026-04-14

Recruiting

All Genders

accepted

18 Years +

440 Estimated Participants

No Expanded Access

Interventional Study

Does not accept healthy volunteers

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.

The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.

Eligibility

Relevant conditions:

Relapsed or Refractory Multiple Myeloma (RRMM)

If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.

locations

Contact Information

Overall Contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

Clinical.Trials@bms.com

855-907-3286

Data sourced from ClinicalTrials.gov